Improving treatments for patients with immune system disorders
Primary Immune Deficiency Treatment Consortium (PIDTC): A resource to drive scientific and clinical advances related to the treatment of inborn errors of immunity
This study is working to improve treatments and care for people with immune system disorders, like Severe Combined Immune Deficiency and Chronic Granulomatous Disease, by gathering information from doctors across the US and Canada to find out what works best for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10935431 on NIH RePORTER |
What this research studies
The Primary Immune Deficiency Treatment Consortium (PIDTC) focuses on enhancing the treatment and outcomes for patients with inborn errors of immunity, such as Severe Combined Immune Deficiency and Chronic Granulomatous Disease. By aggregating data from 49 clinical sites across the US and Canada, the consortium aims to address critical questions regarding treatment effectiveness and patient care. This initiative involves collaboration among immunologists, bone marrow transplant physicians, and cell/gene therapists to develop a comprehensive resource that supports research and clinical advancements in this field.
Who could benefit from this research
Good fit: Ideal candidates for participation include children and adults diagnosed with inborn errors of immunity, particularly those with severe forms of these conditions.
Not a fit: Patients with mild immune deficiencies or those not diagnosed with inborn errors of immunity may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and better health outcomes for patients with severe immune deficiencies.
How similar studies have performed: Previous research efforts in similar areas have shown promise in improving treatment outcomes for patients with immune deficiencies, indicating that this approach has potential for success.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Dvorak, Christopher Craig — University of California, San Francisco
- Study coordinator: Dvorak, Christopher Craig
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.